Treatment outcomes and safety of sequential administration of erlotinib following chemotherapy in patients with erlotinib (as second-line treatment)-resistant advanced non-small cell lung cancer
10.3781/j.issn.1000-7431.2013.11.011
- Author:
Xue-Juan YU
1
Author Information
1. School of Medicine and Life Sciences
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocol;
Carcinoma;
Erlotinib;
Non-small cell lung;
Resistance;
Treatment outcomes
- From:
Tumor
2013;33(11):1002-1007
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the therapeutic efficacy and safety of sequential administration of erlotinib following chemotherapy in patients with erlotinib (as second-line treatment)-resistant advanced NSCLC (non-small cell lung cancer). Methods: Thirty stages ?B-? NSCLC patients with gradual progression after erlotinib treatment as second-line therapy were retrospectively reviewed. Of the 30 patinets, 15 patinets (group A) received one cycle of chemotherapy (pemetrexed plus cisplatin) followed by erlotinib, the remaining 15 patinets (group B) received chemotherapy alone (pemetrexed plus cisplatin). The short-term response and side effects were observed and the survival was analyzed. Results: The objective response rates of group A and group B were 13.3% (2/15) and 6.7% (1/15), respectively (P = 1.000), and the disease control rates were 40.0% (6/15) and 20.0% (3/15), respectively (P = 0.426). The median progression-free survival of group A and group B were 6.0 and 4.0 months, respectively (P = 0.001). There were no significant differences in the rates of side effects between the two groups. Conclusion: The administration of erlotinib following chemotherapy may offer benefits to the patients with erlotinib (as second-line treatment)-resistant advanced NSCLC. This treatment is also generally tolerable. Copyright © 2013 by TUMOR.
